News >

FDA Approves Frontline Atezolizumab Regimen for NSCLC

Gina Columbus @ginacolumbusonc
Published: Thursday, Dec 06, 2018

The FDA has approved atezolizumab (Tecentriq) for use in combination with bevacizumab (Avastin), carboplatin, and paclitaxel (ABCP) for the first-line treatment of patients with metastatic nonsquamous non-small cell lung cancer (NSCLC). The indication excludes patients with EGFR/ALK aberrations. 
... to read the full story
To Read the Full Story

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Publication Bottom Border
Border Publication